Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

Nanoparticles that turn inflammation into propulsion power deliver targeted IBD treatment, enhancing precision and efficacy.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, ...

The underlying cause of inflammatory bowel disease (Crohn’s and ulcerative colitis) still isn’t well-understood. Although ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.

P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis," published in the November 2024 issue of Gastroenterology by Hu et al. Since 2015, CT-P13, a ...

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

For millions of Americans, paying for the treatment needed to manage their diseases can become its own lifelong problem.

Studies have found that Black people may be disproportionately affected by colon cancer in the US, in part because of racism ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the ...